Immuneering Corp. Class A (IMRX)

Over the past six months, Immuneering's stock price has been impacted by earnings reports, analyst ratings, insider activity, short interest, and stock price movement. The company's Q3 2025 and Q2 2025 earnings per share met analysts' expectations. Analysts have maintained a generally positive outlook, with a consensus rating of "Strong Buy" or "Moderate Buy". Insider ownership at Immuneering increased, with consistent insider buying. Short interest in Immuneering recently increased. The stock had fallen by -32.34% over the last month and -9.24% over the last week, but increased by 156.38% between February 3, 2025, and February 2, 2026.

Information regarding the demand seasonality for Immuneering Corp.'s products and services is available through specialized financial platforms but requires a premium account to access and is not publicly available in the provided search results.

Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for cancer patients, operating within the Medical sector. The company uses artificial intelligence and its RABIT platform to design and optimize small-molecule and peptide therapies. Its major product candidates include IMM-1-104 (atebimetinib), an oral MEK inhibitor in Phase 1/2a clinical trials, and IMM-6-415, also in Phase 1/2a clinical trials for solid tumors. The company also has discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications.

Immuneering Corporation is headquartered in Cambridge, Massachusetts, and operates research facilities within the United States. Specific global geographic segmentation data is not readily available.

Immuneering Corp. generally holds a positive reputation within the financial analyst community, as evidenced by a consensus of "Strong Buy" or "Moderate Buy" ratings from multiple analysts. This indicates that financial experts believe the stock is likely to perform well and significantly outperform the market.

Approximately 74.58% of Immuneering Corp.'s shares are held by institutional investors, while company insiders hold about 21.45%. Major institutional owners include Fmr Llc, Sanofi, and Vanguard Group Inc. Top insider stakeholders include Asset Management, Lp Cormorant, President and CEO Benjamin J. Zeskind, and Director Robert J Carpenter.